1Sem.·

Hims & Hers Health launches new category in men's health with focus on treating low testosterone.

$HIMS (+3,68 %)


AI summary:


  • Exclusive collaboration with Marius Pharmaceuticals for the launch of KYZATREX®an FDA-approved oral testosterone preparation (needle-free and injection-free).
  • KYZATREX®:
  • Restores testosterone levels at up to 96 % of men
  • Doubles free testosterone (important for energy, drive, performance)
  • Low side effect profile
  • Effective immediately:
  • Possibility to prescribe customized doses of Enclomiphene (promotes natural testosterone production, maintains fertility).
  • Combination treatment Enclomiphene + Tadalafil for men with sexual symptoms.
  • Start via simple blood test at homeResult in a few days, digital consultation with licensed doctors.
  • From 2026:
  • Introduction of injection-based testosterone therapies via the platform.
  • Goal:
  • Reduce stigmatization, reduce costs, modern & personalized treatment accessible to millions of men.
  • Holistic digital care model with 24/7 support.


Source: Hims Inc. - Hims Launches New Category in Men’s Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments

20
3 Commentaires

image de profil
Very strong news! This will attract new customers in the long term and drive the share price upwards.

However, it is a therapy without an injection and is therefore not injection-based! KI didn't translate it well and you should read it again before you publish it😉
5
image de profil
@Lupo201 Injection-based therapy to arrive in 2026
1
image de profil
@AdriInvests ok that's right, it will come. But the focus is on easier oral intake.
Participez à la conversation